% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Nayak:1027028,
      author       = {Nayak, Lakshmi and Bettegowda, Chetan and Scherer, Florian
                      and Galldiks, Norbert and Ahluwalia, Manmeet and Baraniskin,
                      Alexander and von Baumgarten, Louisa and Bromberg, Jacoline
                      E C and Ferreri, Andrés J M and Grommes, Christian and
                      Hoang-Xuan, Khê and Kühn, Julia and Rubenstein, James L
                      and Rudà, Roberta and Weller, Michael and Chang, Susan M
                      and van den Bent, Martin J and Wen, Patrick Y and Soffietti,
                      Riccardo},
      title        = {{L}iquid biopsy for improving diagnosis and monitoring of
                      {CNS} lymphomas: {A} {RANO} review},
      journal      = {Neuro-Oncology},
      volume       = {26},
      number       = {6},
      issn         = {1522-8517},
      address      = {Oxford},
      publisher    = {Oxford Univ. Press},
      reportid     = {FZJ-2024-03594},
      pages        = {993 - 1011},
      year         = {2024},
      abstract     = {Background: The utility of liquid biopsies is well
                      documented in several extracranial and intracranial
                      (brain/leptomeningeal metastases, gliomas) tumors.Methods:
                      The RANO (Response Assessment in Neuro-Oncology) group has
                      set up a multidisciplinary Task Force to critically review
                      the role of blood and cerebrospinal fluid (CSF)-liquid
                      biopsy in CNS lymphomas, with a main focus on primary
                      central nervous system lymphomas (PCNSL).Results: Several
                      clinical applications are suggested: diagnosis of PCNSL in
                      critical settings (elderly or frail patients, deep
                      locations, and steroid responsiveness), definition of
                      minimal residual disease, early indication of tumor response
                      or relapse following treatments, and prediction of
                      outcome.Conclusions: Thus far, no clinically validated
                      circulating biomarkers for managing both primary and
                      secondary CNS lymphomas exist. There is need of
                      standardization of biofluid collection, choice of analytes,
                      and type of technique to perform the molecular analysis. The
                      various assays should be evaluated through well-organized
                      central testing within clinical trials.Keywords: CSF
                      biomarkers; MYD88 mutations; circulating tumor DNA; primary
                      CNS lymphomas; secondary CNS lymphomas},
      cin          = {INM-3},
      ddc          = {610},
      cid          = {I:(DE-Juel1)INM-3-20090406},
      pnm          = {5252 - Brain Dysfunction and Plasticity (POF4-525)},
      pid          = {G:(DE-HGF)POF4-5252},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {38598668},
      UT           = {WOS:001229686400001},
      doi          = {10.1093/neuonc/noae032},
      url          = {https://juser.fz-juelich.de/record/1027028},
}